

# Steve Boudewijns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9192724/publications.pdf>

Version: 2024-02-01

15  
papers

238  
citations

933447

10  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. <i>Ophthalmology</i> , 2016, 123, 2265-2267.	5.2	44
2	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
3	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. <i>Journal of Immunotherapy</i> , 2016, 39, 241-248.	2.4	26
4	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolmunology</i> , 2016, 5, e1201625.	4.6	21
5	Thirty-minute compared to standardised office blood pressure measurement in general practice. <i>British Journal of General Practice</i> , 2011, 61, e590-e597.	1.4	19
6	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmunology</i> , 2016, 5, e1191732.	4.6	17
7	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	3.3	15
8	Immunological responses to adjuvant vaccination with combined CD1c <sup>+</sup> myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolmunology</i> , 2022, 11, .	4.6	14
9	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>Oncolmunology</i> , 2020, 9, 1738814.	4.6	13
10	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. <i>Journal of Translational Medicine</i> , 2016, 14, 88.	4.4	10
11	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	2.4	7
12	Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2014, 14, 967.	2.6	6
13	Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. <i>Annals of Oncology</i> , 2016, 27, vi362.	1.2	4
14	532 Skin infiltrating lymphocytes as an early biomarker to predict clinical outcome in stage III melanoma patients receiving adjuvant dendritic cell vaccination. <i>European Journal of Cancer</i> , 2015, 51, S114-S115.	2.8	0
15	Abstract IA44: Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome. , 2016, , .		0